Table 2.
Summary of preclinical studies analyzing the role of MDSCs in CRC and therapeutic agents.
| Mouse models | Cells lines | Therapeutic agents | Targets | Ref. |
|---|---|---|---|---|
| C57/BL6 mice | MC38 cells | all-trans-retinoic acid (ATRA) | – | (117) |
| C57/BL6 mice and Nox2-KO mice | MC38 cells | Histamine dihydrochloride (HDC) | NOX2 | (118) |
| C57BL/6 mice | – | Embelin | XIAP | (119) |
| C57BL/6 mice | – | Naringin | – | (120) |
| Balb/c mice | CT26 cells | CSF-1R kinase inhibitors (PLX647 and PLX5622) | CSF-1R | (121) |
| C57/BL6 mice and SCID mice | – | anti-G-CSF mAb | G-CSF | (109) |
| C57BL/6 mice | MC38 cells | anti-DC-HIL mAb | DC-HIL | (122) |
| Balb/c mice | CT26 cells | Curcumin | – | (123) |
| Balb/c mice | CT26 cells | TLR7/8 agonist, R848 | TLR7/8 | (124) |
| C57BL/6 mice,CCR2−/− and CCL2−/− mice | MC38 cells | anti-CCR2 mAb | CCR2 | (125) |
| Balb/c mice and C57BL/6 mice | CT26 cells and MC38 cells | anti-IL-6 mAb | IL-6 | (126) |
| Balb/c mice | CT26 cells | (-)-4-O- (4-O-β-D-glucopyranosylcaffeoyl) quinic acid (QA) | PI3Kδ/γ | (127) |